Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration

Current Vascular Pharmacology

Volumn 9, Issue 5, 2011, Pages 629-646

  Semeraro, Francesco ^a   Morescalchi, Francesco ^a   Parmeggiani, Francesco ^b   Arcidiacono, Barbara ^a   Costagliola, Ciro ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Bleeding; Hypertension; Pegaptanib; Proteinuria; Ranibizumab; Side effects; Stroke

Indexed keywords

AFLIBERCEPT; AL 39324; BEVACIZUMAB; BEVASIRANIB; FLUOROURACIL; PAZOPANIB; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; TG 100801; TG 101095; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; VERTEPORFIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DUODENAL ULCER BLEEDING; ENDOPHTHALMITIS; EPISTAXIS; EYE INFLAMMATION; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; GINGIVA BLEEDING; HEART INFARCTION; HEMATEMESIS; HEMOPTYSIS; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; PHOTODYNAMIC THERAPY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEIN FUNCTION; PROTEINURIA; RECTUM HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; STROKE; SUBDURAL HEMATOMA; THROMBOEMBOLISM; UPPER GASTROINTESTINAL BLEEDING; VAGINA BLEEDING; VISUAL ACUITY; WOUND BLEEDING;

ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; HUMANS; INTRAVITREAL INJECTIONS; LIGANDS; MACULAR DEGENERATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80051778087     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796642670     Document Type: Article

References (213)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Preva lence Research Group. Prevalence of age-related macular degenera tion in the United States. Arch Ophthalmol 2004; 22: 564-572.
2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalm 2004; 137: 486-495.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2004; 9: 669-676.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
5. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1981; 161: 851-858.
6. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc UK 1948; 68: 137-180.
7. The Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology 1978; 85: 82-106.
8. Branch Vein Occlusion Study Group: Argon laser scatter photoco-agulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol 1986; 104: 34-41.
9. th Edition. Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP (Eds.), Elsevier, London, UK 2006: 1240-1270.
10. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
11. Keck PJ, Hauser SD, Krivi, G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
12. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
13. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithe-lial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-1326.
14. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor. J Biol Chem 1992; 267: 26031-26037.
15. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-691.
16. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86: 346-355.
17. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-11714.
18. Carmeliet P, Ferreira V, Breier, G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
19. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990; 8: 519-527.
20. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyro-sine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 1992; 52: 5738-5743.
21. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentia-tion of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
22. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
23. Bauer SM, Bauer RJ, Liu ZJ, et al. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in threedimensional collagen gels. J Vasc Surg 2005; 41: 699-707.
24. Yonekura H, Sakurai S, Liu X, et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvas-cular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 1999; 274: 35172-35178.
25. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
26. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angio-genesis. J Clin Invest 1989; 84: 1470-1478.
27. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothe-lial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996; 81: 353-359.
28. Zlokovic BV. Remodeling after stroke. Nat Med 2006; 12: 390-391.
29. Infanger M, Faramarzi S, Grosse J. Expression of vascular endothe-lial growth factor and receptor tyrosine kinases in cardiac ische-mia/reperfusion injury. Cardiovasc Pathol 2007; 16: 291-299.
30. Larsson A, Sköldenberg E, Ericson, H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 2002; 5: 107-110.
31. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-14.
32. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
33. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endo-thelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30366-30443.
34. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
35. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: 14765-14770.
36. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: 560-576.
37. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
38. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
39. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
40. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1999; 59: 4129-4135.
41. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tu-mor using endothelial growth factor. Cancer Res 1999; 59: 4129-4135.
42. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002; 99: 11946-11950.
43. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue beyond blood vessels. Exp Neurol 2004; 187: 246-253.
44. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmè D. Migration of human monocytes in response to vascular endothe-lial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343.
45. Martin AC, Thornton JD, Liu J, et al. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest. Ophthalmol Vis Sci 2004; 45: 3387-3396.
46. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167: 1451-1459.
47. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-4747.
48. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angio-genic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
49. Gogat K, Le Gat L, van den Berghe L, et al. VEGF and KDR gene expression during human embryonic and fetal eye development. Invest Ophthalmol Vis Sci 2004; 45: 7-14.
50. Safran M, Kaelin WJ Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-783.
51. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90: 1542-1547.
52. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421-428.
53. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthal-mol Vis Sci 1999; 40: 2115-2121.
54. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-584.
55. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114: 1219-1228.
56. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
57. Malecaze F, Clemens S, Simorer-Pinotel V, et al. Detectionof vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-1482.
58. Shima D, Adamis AP, Ferrara N, et al. Hypoxic induction of endo-thelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol Med 1995; 2: 182-193.
59. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
60. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a non-human primate. Arch Ophthalmol 1996; 114: 66-71.
61. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996; 93: 4851-4856.
62. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularisation. Am J Pathol 2000: 156: 697-707.
63. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997; 29: 354-362.
64. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothe-lial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80: 363-366.
65. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularisation. Am J Pathol 1997; 151: 281-291.
66. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endo-thelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Oph-thalmol Vis Sci 1996; 37: 855-868.
67. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
68. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovas-cular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-1934.
69. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Oph-thalmol 1997; 8: 154-162.
70. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularisation. Am J Pathol 2000; 157: 135-144.
71. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch' s membrane, the choriocapillaris, and the choroid in aging. Invest Oph-thalmol Vis Sci 1994; 35: 2857-2864.
72. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothe-lial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
73. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
74. Ferrara N, Hillan KJ, Gerber HP, Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
75. Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007; 55: 417-420.
76. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
77. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
78. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-998.
79. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
80. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascu-larization in age-related macular degeneration. Retina 2007; 27: 445-450.
81. Pedersen R., Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007; 85: 526-533.
82. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizu-mab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245: 215-220.
83. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85: 563-565.
84. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008; 86: 482-489.
85. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am. J Ophthalmol 2007; 143: 510-512.
86. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008; 52: 52-56.
87. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (A-vastin) therapy vs. photodynamic therapy plus intravitreal triamci-nolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92: 356-360.
88. Costagliola C, Semeraro F, Cipollone U, Rinaldi M, della Corte M, Romano MR. Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthal-mol 2009; 247: 1031-1037.
89. Costagliola, C, Romano M, Corte MD, et al. Intravitreal bevacizu-mab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 2009; 29: 1227-1234.
90. Bashshur ZF, Schakal, A, Hamam RN, et al. Intravitreal bevacizu-mab vs. verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125: 1357-1361.
91. Tufail A, Patel PJ, Egan C, et al. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010; 340: c2459.
92. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Eng J Med 2006; 355: 1409-1412.
93. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizu-mab (Avastin) for occult choroidal neovascularisation in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2007; 245: 941-948.
94. Conrad PW, Zacks DN, Johnson MW Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovacular age -related macular degeneration. Clin Ophthalmol 2008; 2: 727-733.
95. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Ad-amis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132.
96. Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005; 102: 18902-18907.
97. Waheed NK, Miller JW. Aptamers, intramers, and vascular endo-thelial growth factor. Int Ophthalmol Clin 2004; 44: 11-22.
98. Ishida S, Usui T, Yamashiro K, et al. VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularisation. J Exp Med 2003; 198: 483-489.
99. Ishida S, Usui T, Yamashiro K, et al. VEGF 164 is proinflamma-tory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-2162.
100. Ng E, Nishijima K, Robinson GS, Adamis AP, Shima DT. VEGF has both direct and indirect neuroprotective effects in ischemic retina. Invest Ophthalmol Vis Sci, 2006; 4: 4829.
101. Özkiris A. Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat 2010; 20: 103-118.
102. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
103. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Chakravarthy U, Adamis AP, Cunningam ET Jr, Katz B, Patel M. Year 2 efficacy results of 2 randomised controlled clinical trials of pegaptanib for neovascular age related macular degeneration. Ophthalmology 2006; 113: 1508-1525.
104. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Trial. Br J Ophthalmol 2008; 92: 1606-1611.
105. Rosenfeld PJ, Brown DM, Heier, JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
106. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab vs. verte-porfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
107. (2006) Lucentis [package insert]. San Francisco,Calif. Genentech Inc.
108. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509-1513.
109. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ra-nibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
110. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Oph-thalmol 2009; 148: 43-58.
111. Lucentis at one year. Available at http://www.eyeworld.org/prin-tarticle.php?id=4390.
112. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthal-mol 2008; 145: 239-248.
113. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R. On behalf of the EXCITE study group. Visual Acuity Response Profiles in Patients With Neovascular Age-related Macular Degeneration Treated Quarterly With Ranibizumab in the EXCITE Trial. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 2374.
114. Kirchhoff B, Kellner U, Holz FG, Schlingemann RO On behalf of the SUSTAIN study group. Visual Acuity and Central Retinal Thickness Response Profiles and Treatment Patterns in Patients With Neovascular AMD Treated With Ranibizumab in the SUSTAIN Study. Invest Ophthalmol Vis Sci 2009 50: E-Abstract 2366.
115. Heier JS, Boyer DS, Ciulla TA, et al. FOCUS Study Group. Ra-nibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-1542. Erratum in: Arch Ophthalmol 2007; 125: 138.
116. Antoszyk AN, Tuomi L, Chung CY, Singh A. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-874.
117. Schmidt-Erfurth U, Wolf S. PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008; 92: 1628-1635.
118. ®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 3093.
119. ®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87.
120. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008; 68: 1029-1036.
121. Safety & Efficacy Study Evaluating the Combination of Bevasira-nib & Lucentis Therapy in Wet AMD (COBALT). [ClinicalTri-als.gov identifier: NCT00499590]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT0049 9590.
122. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campo-chiaro PA. Suppression and regression of choroidal neovasculariza-tion by the multitargeted kinase inhibitor pazopanib. Arch Oph-thalmol 2009; 127: 494-499.
123. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD. [ClinicalTrials.gov identifier: NCT00612456]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00612456.
124. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovasculari-zation and retinal edema. J Cell Physiol 2008; 216: 29-37.
125. Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. [ClinicalTrials.gov identifier: NCT00509548]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00509548.
126. Chen ZZ, Mak C, Renick J, et al. A Dual VEGFR/JAK2 Kinase Inhibitor Suitable for Topical Delivery Inhibits Choroid Neovascu-larization in Mice. Invest Ophthalmol Vis Sci 2007; 48: E-Abstract 1469.
127. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243: 593-600.
128. Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD). [ClinicalTrials.gov identifier: NCT00138632]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00138632.
129. Bingaman DP, Gu X, Landers RA, et al. AL-39324 is more potent and efficacious against ocular NV vs. other RTKi's. Invest Oph-thalmol Vis Sci 2007; 48 (5) [abstract no. E-1747].
130. Kuppermann BD. Drug delivery strategies for combination ophthalmic treatments. Retina 2009; 29: 24-26.
131. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Oph-thalmol 2009; 148: 43 el-58 el.
132. Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51: 405-412.
133. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
134. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOL-FOX4) for previousltreated metastatic colorectal cancer: results fromEastern Cooperative Oncology Group Study E3200. Oncol 2007; 25: 1539-1544.
135. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
136. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus combination interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
137. Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
138. US Food and Drug Administration. MedWatch. Barron, H. Genen-tech. Important drug warning (letter). http://www.fda.gow/ med-watch/Safety/2005/Avastindearhcp.pdf. 2005
139. Vinores SA, Derevkanik NL, Ozaki H, et al. Cellular mechanism of blood-retinal barrier dysfunction in macular edema. Doc Ophthal-mol 1999; 97: 217-228.
140. Couper D, Lai H, Hubbard LD, et al. Age-related macular degeneration and risk of stroke. Ann Intern Med 2006; 145: 98-107.
141. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007; 114: 732-737.
142. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age related macular degeneration in the UK. Pharmacoeconomics 2007; 25: 863-879.
143. Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009; 54: 339-348.
144. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000; 17: 1503-1510.
145. Gaudreault J, Fei D, Rusit, J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-733.
146. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218.
147. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982; 26: 207-218.
148. www.pfizer.com/products/rx_product_macugen.jsp.
149. Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacokinet-ics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 1999; 29: 579-585
150. Shahar J, Avery L, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab. Retina 2006; 26: 262-269.
151. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration bof bevaci-zumab through the retina after intravitrea administration in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823.
152. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacoki-netics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859.
153. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizu-mab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705.
154. Mennel S, Callizo J, Schmidt JC, Meyer CH. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 2007; 85: 689-691.
155. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
156. Genentech. Highlights of prescribing information. Lucen-tis.http://www.fda.gov/cder/foi/label/2006/125156lbl.pdf
157. La Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? Acta Ophthalmol Scand 2007; 114: 855-859.
158. Macugen AMD Study Group 2007. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age related macular degeneration. Ophthalmology 2007; 114: 1702-1712.
159. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of in-travitreal ranibizumab (lucentis). Ophthalmology 2007; 114: 2179-2182.
160. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age related macular degeneration in the UK. Pharmacoeconomics 2007; 25: 863-879.
161. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Developmant of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870.
162. Avery RL. New treatments for age-related macular degeneration. Lancet 2007; 370(9597): 1479-1480; author reply 1480.
163. Ziemssen F, Zhu Q, Peters S, et al. Tuebingen Bevacizumab Study Group, Ziemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009; 29: 213-224. Epub 2008 Apr 17.
164. Cohen, MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second line treatment of colorectal cancer. Oncologist 2007; 12: 356-361.
165. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
166. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevaci-zumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
167. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? Eur J Cancer 2009; 45: 2452-2461.
168. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial throm-boembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9. Epub 2007 Aug 8. Erratum in: J Natl Cancer Inst 2008; 100: 156. J Natl Cancer Inst 2008; 100: 685.
169. Zachary, I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280: C1375-C1386.
170. Mete A, Saygili O, Mete A, Bayram M, Bekir N. Effects of in-travitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 2010; 38: 66-70.
171. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010; 88: 263-266. Epub 2009 Apr 8.
172. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
173. Boyer DS, Chung CY, Tuomi LA. A safety overview of ranibizu-mab in patients with wet AMD: ANCHOR, MARINA, PIER, and SAILOR (2008) Presented at the Annual Meeting of the American Academy of Ophthalmology, November 8 to 11,Atlanta, Georgia.
174. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 158-165.
175. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucen-tis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13. Epub 2009 May 13.
176. Chong NV. Should avastin be used to treat age-related macular degeneration in the NHS?--No. Eye (Lond) 2009; 23: 1250-1253.
177. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T: Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116: 362.
178. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349. Epub 2006 Jul 19.
179. IVAN: a randomised controlled trial of alternative treatments to inhibit VEGF in age related choroidal neovascularisation. University of Bristol, 2009. http://cteu.bris.ac.uk/trials/ivan/.
180. VIBERA Trial: Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (http://clinicaltrials.gov/ct2/show/NCT00559715).
181. CATT study: Comparison of AMD Treatment Trials: Lucentis-Avastin Trial, National Eye Institute, 2008 www.clinicaltrials.gov.
182. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. (2007) Br J Cancer 2007; 96: 1788-1795.
183. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-H1058.
184. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006; 40: 2278.
185. Sane DC, Anton L, Brosnihan KP. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
186. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: S25-S33.
187. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-934.
188. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
189. Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs 2005; 9: 407-411.
190. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2010 Oct 22. [Epub ahead of print]
191. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008; 86: 372-376.
192. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
193. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
194. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinu-ria. J Biol Chem 2003; 278: 12605-12608.
195. Campos S, Dizon DS, Cannistra SA, et al. Safety of consolidation bevacizumab after first line chemotherapy for advanced ovarian cancer. J Clin Oncol 2007; 25: 278s.
196. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
197. Johnson DH, Fehrenbacher L, Novotny et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
198. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracra-nial bleeding during anti-VEGF therapy? Neuro Oncol 2008; 10: 624-630.
199. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-1802.
200. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542.
201. Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12: 793-800.
202. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-1739.
203. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoen-cephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63: 1475-1478.
204. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology 2006; 20(14 Suppl 10): 1-8.
205. Bates DO, Jones RO. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2003; 2: 107-120.
206. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
207. Ko J, Ross J, Awad H, Hurwitz H, Klitzman B. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res 2005; 129: 251-259.
208. Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP. Cost-utility analysis of bevacizumab vs. ranibizumab in neovascular age-related macular degeneration using a Markov model. J Eval Clin Pract 2010 Sep 16. [Epub ahead of print]
209. Neubauer AS, Holz FG, Sauer S, et al. Cost-effectiveness of ra-nibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system. Clin Ther 2010; 32: 1343-1356.
210. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lel-gemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010; 21: 218-226.
211. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovas-cular macular degeneration. Ophthalmology 2008; 115: 1039-1045.
212. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009; 116: 481-487.
213. Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets 2011; 12: 149-172.